Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2125)	1/14/2008 5:17:02 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 3722

Take a look at Helicos, HLCS--about the same marketcap as Sequenom now, not too shabby--both have done suprisingly well. For that matter, how did Illumina get to be a $4B company while Affymetrix has languished? finance.yahoo.com (not that the chart will tell you why, but charts are indeed fun--especially after the fact) The success of tool companies cannot be attributed to personalized medicine--not for real anyway. The false promises of genomics weren't suddenly realized while I wasn't paying attention?

To: Jibacoa who wrote (2125)	2/21/2008 2:07:31 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

SQNM Tried to get above the $8 level, but was brought down again by the general market.<g> bigcharts.marketwatch.com The shares rose early today after SQNM sid it expects a strong rise in 2008 revenue & announced plans to launch a genetic test product.It said yesterday that it expects a loss for 2008 between $30M to $33M vs. the loss of $20.9M in 2007. It projected 2008 revenue of $53M to $56M, which would be a 30% to 37% improvement from 2007.It also expects gross margin to improve & expects to launch its noninvasive genetic test for Down syndrome in the first half of 2009. The "analysts" have a target around $13 to $15 for SQNM. I will wait to see if the stock can find support at the $7.25 level.<g> bigcharts.marketwatch.com Bernard